Targeting a rare, fatal brain cancer with spherical nucleic acids

The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the FDA as an investigational drug for clinical investigation in the deadly brain cancer glioblastoma multiforme.
A clinical trial will be launched this spring at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine. ____
▶️ Subscribe: bit.ly/Northwe...
Follow Northwestern on social media:
-Instagram: / northwesternu
-TikTok: / northwestern.u
-Twitter/X: / northwesternu
-LinkedIn: / northwestern-university
-Facebook: / northwesternu
Northwestern on the Web:
-Northwestern Homepage: northwestern.edu
-Northwestern Now News: news.northwest...
-Northwestern Magazine: magazine.north...